Valuation: Sanofi SA

Market Cap 92.37B 105B 85.75B 78.8B 148B 10,173B 151B 1,022B 400B 4,978B 396B 387B 17,196B P/E 2026 *
11.6x
P/E 2027 * 10.6x
Enterprise Value 102B 116B 94.69B 87.02B 164B 11,234B 166B 1,128B 442B 5,497B 437B 428B 18,988B EV / Sales 2026 *
2.17x
EV / Sales 2027 * 1.96x
Free-Float
89%
Yield 2026 *
5.54%
Yield 2027 * 5.86%
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 57 2020-04-27
Director/Board Member 64 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+1.42%-1.47% - - 105B
-1.05%+0.55%+49.79%+151.71% 1,037B
+2.00%+3.49%+52.22%+50.20% 615B
-1.09%+3.76%+35.37%+76.22% 448B
+2.80%+3.17%+30.92%+25.08% 326B
-0.78%+1.05%+33.76%+37.18% 293B
-1.18%-0.45%+17.77%+16.61% 264B
-1.52%-6.48%-29.08%-42.90% 216B
-0.05%+2.16%+19.75%+55.89% 198B
+0.05%-1.03%+18.31%+61.63% 162B
Average -0.07%+1.12%+25.42%+47.96% 395.27B
Weighted average by Cap. -0.12%+1.47%+35.09%+72.40%

Financials

2026 *2027 *
Net sales 46.94B 53.58B 43.58B 40.05B 75.46B 5,170B 76.57B 519B 203B 2,530B 201B 197B 8,739B 50.04B 57.11B 46.45B 42.69B 80.44B 5,511B 81.62B 553B 217B 2,696B 214B 210B 9,315B
Net income 8.33B 9.51B 7.73B 7.11B 13.39B 917B 13.59B 92.13B 36.06B 449B 35.69B 34.92B 1,551B 9.22B 10.53B 8.56B 7.87B 14.83B 1,016B 15.05B 102B 39.93B 497B 39.52B 38.67B 1,717B
Net Debt 9.63B 10.99B 8.94B 8.22B 15.48B 1,061B 15.71B 107B 41.69B 519B 41.26B 40.37B 1,793B 5.52B 6.3B 5.12B 4.71B 8.87B 608B 9B 61.04B 23.89B 297B 23.65B 23.14B 1,027B
Logo Sanofi SA
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-